Wang L et al. demonstrated that in prostate cancer, GIPC2 can directly bind to Fzd7 through its PDZ structural domain, which activates the Wnt/β-catenin cascade to promote metastasis of prostate cancer cells (Wang et al. 2022a, b). Here, GIPC2 is linked to prostate carcinoma.